InMed Pharmaceuticals (INM) Net Equity Issued and Repurchased (2021 - 2023)

InMed Pharmaceuticals' Net Equity Issued and Repurchased history runs 3 years deep, the most recent figure standing at $174.0 for Q1 2023.

• On a quarterly basis, Net Equity Issued and Repurchased changed N/A year-over-year to $174.0 in Q1 2023; TTM through Jun 2023 was $12.0 million, a 30.01% decrease from a year earlier, with the FY2023 full-year figure at $12.0 million, down 30.01% from the prior year.
• Net Equity Issued and Repurchased fell to $174.0 in Q1 2023 per INM's latest filing, from $6.0 million in the prior quarter.
• Across five years, Net Equity Issued and Repurchased topped out at $12.0 million in Q3 2021 and bottomed at $174.0 in Q1 2023.
• The 3-year median for Net Equity Issued and Repurchased is $5.1 million (2022), against an average of $4.8 million.
• Biggest YoY gain for Net Equity Issued and Repurchased was 3408932.39% in 2022; the steepest drop was 50.0% in 2022.
• Year by year, Net Equity Issued and Repurchased stood at $176.0 in 2021, then soared by 3408932.39% to $6.0 million in 2022, then tumbled by 100.0% to $174.0 in 2023.
• Per Business Quant, the three latest INM Net Equity Issued and Repurchased figures stand at $174.0 (Q1 2023), $6.0 million (Q4 2022), and $6.0 million (Q3 2022).